Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Blue Sky Uranium Schedules Start of Drill Program for Ivana Uranium-Vanadium Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Esperion Therapeutics Inc
ESPR
Healthcare
Biotechnology
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and...
NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ESPR)
New Post
View:
Posts & Comments
Threaded Posts
(216)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Dec 02, 2024 3:33pm
This stock is a good buy
Buy Order was filled at $2.83 cents per share today and this one should do well for all of us shareholders.
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 5:05pm
Esperion Therapeutics, Inc.: Delivering Impressive Growth an
https://beyondspx.com/2024/07/31/esperion-therapeutics-inc-delivering-impressive-growth-and-expanded-indications/
QMET Announce Initial Results And Targeted Exploration Plan for Project In Nova Scotia
posted May 22, 2025 9:00am by
Q Precious & Battery Metals Corp.
-
|
Richard Penn, CEO of Q Precious & Battery Metals, commented: "These initial results from Colchester underscore the exceptional efficiency of QIMC’s exploration approach. The rapid identification of priority targets positions us strongly for the next exploration phase." ...read more
(4)
•••
AviseAnalytics
X
Post by
AviseAnalytics
on Jul 15, 2024 9:05am
ESPERION: REVOLUTIONIZING THE PHARMA INDUSTRY
$ESPR Excited to share an article about Esperion Therapeutics Inc. (NASDAQ: ESPR), a pharmaceutical company that focuses on developing and commercializing accessible, oral
...more
(12)
•••
edrose
X
Post by
edrose
on Mar 23, 2023 2:17pm
When will judge make decision
Agreement should be clear re milestones
(12)
•••
edrose
X
Post by
edrose
on Mar 09, 2023 3:54pm
It lowers ldl but bigger question does it decrease
Heart attacks, and mortality
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Developing a sizeable copper resource with a highly prospective exploration asset in Peru
Identifying new compelling targets on extensive and highly prospective land position